predictions of future events aren’t actionable false advertising

Duty Free Americas, Inc. v. Estée Lauder Cos., 2014 WL 1329359, No. 12–60741 (S.D. Fla. Mar. 31, 2014)

This is mostly an antitrust case; the antitrust claims are all dismissed because no one wins antitrust cases.  DFA operates duty-free stores in airports, with beauty products a major category.  ELC supplies many duty-free stores with beauty products, but no longer deals with DFA.  DFA sued for attempted monopolization, tortious interference with prospective business relationships with three airports, and contributory false advertising.  The dismissal was with prejudice for everything but the contributory false advertising claim, but the court cautioned that DFA shouldn’t try again without keeping Rule 11 in mind, since there’d already been amended complaints and extensive discovery.

Because of a past dispute on pricing, DFA stopped carrying ELC products and ELC refused to deal with DFA when DFA changed its mind.  Various people said they thought DFA misrepresented its ability to sell ELC products during bidding on airport contracts.  For example, one person connected to ELC wrote that “DFA does not have authority to offer our product lines in their operations” and “DFA is not authorized to represent that it has ability to sell Estée Lauder Companies/ brands in its stores.” DFA alleged that these statements were untrue because it still had ELC products in inventory, though DFA didn’t allege that ELC knew or had reason to know DFA’s inventory. For one airport contract, another bidder accused DFA of misrepresentations of its ability to carry ELC products.

ELC didn’t unjustifiedly interfere with business relations because it acted to safeguard its own financial interests and didn’t employ improper means in doing so.  The representations that ELC made itself, as opposed to the representations that other duty-free operators made about the ELC-DFA relationship, were truthful.  And ELC promoted its own financial interest by telling airports about the duty-free operators it dealt with and that it didn’t deal with DFA: doing so increased the likelihood that the airport would select an operator who sold ELC.  Similarly, it wasn’t improper to tell other duty-free operators that ELC didn’t do business with DFA.  And DFA didn’t allege facts that would allow the court to impute allegedly false representations by duty-free operators to ELC.  The other operators were separate companies, and there was no allegation of conspiracy.  The other operators did claim that because DFA didn’t carry ELC, its financial terms offered to airports were unrealistic—but ELC never said that.

Lanham Act contributory false advertising: DFA failed to allege a plausible claim of underlying direct liability.  The statements that DFA alleged were false were “merely predictions about sales prospects,” and thus were opinions.  The statements: “Given that Estée Lauder brands account for 20% of cosmetic and fragrance sales, at least in Orlando, and cosmetic and fragrance sales constitute one of the largest sources of revenue for duty free stores, a lack of access to Estée Lauder brands would cast doubt on the validity of DFA’s projected revenue streams”; “[W]e strongly believe that Estée Lauder is a product which you have to sell, also, to domestic passengers”; “DFA sales projects are deemed to be unreasonable and not sustainable in light of the history”; “[F]ailure to offer the Estée Lauder product line will negatively impact duty free and duty paid sales revenue for both international and domestic travelers.”  These were all “predictions that do not lend themselves to empirical verification.”  They used language signaling a prediction, and they were about future commercial events.  (Presumably the court uses “commercial” because some predictions—like “this drug reduces complications 35%”—are empirically verifiable because probabilistic.)

The exception to the opinion rule is where the speaker knows facts that make the opinion false/not held in good faith.  But DFA didn’t allege that the operators here knew their statements to be false or lacked a good faith basis for believing them. It was (more) plausible that they genuinely believed the statements. After all, they put up with onerous ELC conditions (described in the antitrust section), and it was unreasonable to assume that operators would do so if they didn’t believe that selling ELC products was an advantage.
Posted in antitrust, http://schemas.google.com/blogger/2008/kind#post | Leave a comment

using metatags/buying AdWords isn’t trademark use

Radiancy, Inc. v. Viatek Consumer Products Group, Inc., 2014 WL 1318374, No. 13–cv–3767 (S.D.N.Y. Apr. 1, 2014)

And now for a different result on the pleading standards for affirmative defenses!  Among the many arguments in this case, Viatek raised unclean hands as an affirmative defense.  Here, Radiancy alleged that Viatek used Radiancy’s trademark in its website metadata, directed Google search results to Viatek’s product, and falsely advertised that its hair removal devices caused hair growth to stop. Viatek alleged that Radiancy was also using Viatek’s trademark in Radiancy’s website metadata; trying to influence Google searches; and advertising that its hair removal devices could stop hair growth.  But pleading “unclean hands” without more isn’t enough.  Radiancy would be prejudiced by not striking a bare unclean hands defense because additional discovery would be required.

Here, the court found that Viatek wasn’t sufficiently clear about the false advertising aspects of the defense. However, the trademark-related claims were sufficiently clear that the defense survived with respect to them.

As for Viatek’s unfair competition counterclaim, at the pleading stage, “there must at least be allegations of the goods allegedly misappropriated or marketed to the public, how such goods competed with those of the counterclaim-plaintiff, the basis upon which the consuming public would be confused, and the damages sustained.”  Viatek couldn’t base its claim on allegations of bad faith litigation, because that doesn’t give rise to an unfair competition claim under NY law.

What about the metatag/keyword buys claims?  Somewhat puzzlingly, the court relied on 1–800 Contacts v. When U.Com, Inc., 414 F.3d 400 (2d Cir. 2005), rather than Rescuecom v. Google. Since internal use of a mark as a keyword isn’t use of a mark in a trademark sense, and since Radiancy didn’t place the mark on any goods, displays, etc. or use the mark in any way that indicated source or origin, Viatek didn’t state a claim for unfair competition under the Lanham Act. It is odd that Google is “using” the mark in the Second Circuit but, according to this case, Google’s advertisers aren’t—and yet I can’t find any great sadness in me for this result, since neither metatags nor keyword buys in themselves indicate anything about likely confusion.
Posted in http://schemas.google.com/blogger/2008/kind#post, procedure, trademark | Leave a comment

Twiqbal doesn’t apply to unclean hands defense

Newborn Bros. Co. v. Albion Engineering Co., No. 12–2999, 2014 WL 1272109 (D.N.J. Mar. 27, 2014)

Newborn sued its competitor Albion for allegedly falsely advertising its dispensing guns (used to apply sealants and adhesives) as made in the US when Albion knew they were made in Taiwan.  Late in the game, Newborn moved to strike Albion’s late-pled unclean hands defense (apparently that Newborn’s products were also falsely advertised as made in the US).  First, the court found that affirmative defenses aren’t required to be pled with the specificity required by Iqbal/Twombly.  Newborn also argued that Rule 9(b) applied to the extent that the counterclaim was fraud-like; the court was sympathetic, and indicated that it likely would have granted a Rule 9(b) motion with leave to amend if the issue had been raised before discovery. But given the timing, the court wasn’t going to let Newborn use 9(b) as a sword, “when it was designed to act as a shield against frivolous or unclear allegations of fraud.”  At this point, Newborn had adequate notice of the factual basis for the defense and opportunity to rebut it.

The court confirmed that unclean hands is a viable defense to Lanham Act claims.  If there was no factual support for the defense, Newborn had other remedies at the appropriate stage of litigation.
Posted in http://schemas.google.com/blogger/2008/kind#post, procedure | Leave a comment

Statements about quality care were puffing despite standard of care

Intermountain Stroke Center, Inc. v. Intermountain Health Care, Inc., No. 2:13–cv–00909, 2014 WL 1320281 (D. Utah Mar. 31, 2014)

ISC sued IHC for violations of the Lanham Act and Utah’s Truth in Advertising Act and intentional interference with actual/prospective economic relations. The court dismissed the Lanham Act claims and declined to exercise jurisdiction over the state law claims.  IHC offers insurance plans and operates hospitals and clinics. ISC treated strokes and transient ischemic attacks (TIA)until it closed, allegedly as a result of IHC’s conduct. 

Though the standard of care for stroke and TIA allegedly requires that the patient either be immediately hospitalized or be seen within forty-eight hours at a same-day, urgent-care stroke clinic, plaintiffs alleged that IHC frequently saw stroke and TIA patients in IHC emergency rooms, failed to hospitalize such patients, and refused to refer them to the Stroke Center—the only same-day, urgent-care stroke clinic in Utah.  Treatment at the Stroke Center was not covered by IHC insurance, so many stroke and TIA patients were allegedly forced to settle for IHC’s allegedly sub-standard treatment.  IHC allegedly misled consumers about their care, misrepresenting that ICH provided high quality care with the best medical practices.  IHC’s advertising allegedly misled consumers to believe that IHC employs many specialists in stroke/TIA treatment when it has almost no one in those categories, and to believe that IHC carefully complies with federal laws that ban rewarding doctors for referrals even though IHC recently settled with DoJ for violations of those laws.

The court found that the complaint didn’t state a plausible claim for relief; many of the challenged statements weren’t statements of fact and the rest weren’t adequately alleged to be misleading or give rise to a competitive injury.

Non-fact: IHC’s claim to provide “high quality care,” “the best possible care,” “excellent care of the highest quality at an affordable cost,” and that it employs “best medical practices” were puffery as a matter of law.  These were “vague generalities that no reasonable person would rely on as assertions of particular facts.” Plaintiffs argued that these statements were objectively false because IHC fell below the standard of care for stroke and TIA patients. But literal falsity isn’t dispositive; the question is whether any reasonable person would rely on the assertions.  As a well-worn old case says, puffery is “a seller’s privilege to lie his head off, so long as he says nothing specific, on the theory that no reasonable man would believe him, or that no reasonable man would be influenced by such talk.”  (Raising as always the question of why advertisers use it.)  “Claims as to high quality and low cost—even if linked to a particular product or service and even if false—are paradigmatic examples of puffery upon which no reasonable person would be expected to rely.”

Plaintiffs argued that “best medical practices” had a specific referent, the standard of care.  (Example statement: “all three Intermountain divisions—Health Services, SelectHealth, and the Intermountain Medical Group—contribute in essential ways to the sharing of best medical practices, and raising the standards of clinical excellence.”)  But this statement wasn’t made in the context of any particular product or service.  Even if the claims were made about stroke and TIA services in particular, they still would be too vague.  If IHC specifically stated that its practice of refusing to either hospitalize stroke and TIA patients or to refer such patients to a same day stroke or TIA clinic is in accord with the best medical practices, plaintiffs could state a claim, but IHC wasn’t alleged to have done that.  Also, the “best medical practices” statements were phrased to suggest puffery, without defining the term.  “Whatever exactly it means to ‘contribute in essential ways to the sharing of best medical practices,’ no reasonable consumer would rely on the claim in choosing IHC as its stroke and TIA treatment provider.”

Plaintiffs also alleged that IHC misled patients and consumers to believe that it employs more specialists in stroke and TIA treatment than it in fact does.  The court found its statements true and not misleading.  Stroke care isn’t its own category on the IHC website.  It’s listed under “Heart and Vascular Services.” IHC’s “Find a Doctor” link from its stroke care page provides a list of heart and vascular surgeons, but not vascular neurologists or stroke specialists. Plaintiffs argued that these features induced consumers to falsely believe that the heart and vascular physicians employed by IHC specialize in stoke and TIA treatment.

The court found that implausible. Next to each doctor’s name is his or her primary area of specialization, and clicking on the name gives more information, including additional areas of specialization, practice areas, and board certifications. None of the information says they specialize in stroke or TIA treatment.  “The fact that the list is accessible from the stroke care portion of IHC’s website may suggest that some of the physicians listed are competent to provide stroke and TIA treatment.”  But plaintiffs didn’t allege that such an implication was false, only that they weren’t specialists.  “Given the extensive information regarding the physicians’ areas of focus and specialization, there is no reason to believe that patients or consumers would infer that some or all of those physicians specialize in—and do not merely have competence with respect to—the treatment of stroke.” The Lanham Act didn’t require an affirmative warning here.

Similarly, IHC’s advertising for its Neuroscience Institute—advertised as offering stroke patients with resources for “ongoing medical needs after hospitalization” and employing “subspecialists including epileptologists, general neurologists, physical medicine and rehabilitation physicians, and neuropsychologists”—wouldn’t mean anything more to consumers than what it says; consumers wouldn’t likely receive the message that these providers are subspecialists in treating stroke.

As for IHC’s statements about its code of ethics/anti-kickback practices, IHC’s claims were true and not misleading.  IHC said it

carefully review[s] financial relationships with physicians and other health care practitioners for compliance with the anti-kickback and Stark laws. All financial arrangements and contracts with physicians and physician groups must have legal Department review. Intermountain will not improperly induce or reward referrals of patients or services as prohibited under these laws and regulations.

Plaintiffs alleged that IHC’s refusal to refer patients to the Stroke Center or provide insurance coverage for treatment inappropriately created revenue for IHC, and that ICH recently settled claims with DoJ over a compensation arrangement that improperly rewarded physicians for referrals in violation of federal law.

The court held that this statement didn’t suggest that IHC or its employees uniformly meet the ethical standards outlined in the Code of Ethics, which set out disciplinary action for violations and told everyone to report suspected violations.  “In recognizing a potential violation of one of its ethical standards, reporting that violation, and accepting the consequences [with DoJ, IHC acted in exactly the way contemplated by the Code of Ethics.” Likewise, IHC’s standard regarding the avoidance of “actions that inappropriately create revenues” didn’t make its decision not to do business with the Intermountain Stroke Center false advertising.

Plus, plaintiffs didn’t plausibly allege competitive injury from these statements. Their allegations of injury were conclusory, and the alleged misrepresentation wasn’t about IHC’s stroke care but about its business operations generally.  It wasn’t plausible that a consumer trying to decide about stroke treatment would be influenced by these statements in a Code of Ethics intended primarily for IHC employees. The Stroke Center may have suffered harm, but not from the alleged misrepresentation.

Finally, IHC’s pamphlet—“Life After a Stroke or TIA”—was also nonmisleading.  The pamphlet’s entry on “Aftercare” said that “[i]n the first few weeks after your discharge, you’ll need to see members of your medical team. Use the chart below to keep track of these important appointments.” The second entry on the included chart is for an appointment with a neurologist and provides that the appointment is “usually recommended 4 to 6 weeks after you leave to go home.” Plaintiffs argued that IHC’s pamphlet was likely to mislead TIA patients to believe that they can “safely wait 4 to 6 weeks before following up with a neurologist.”  Though plaintiffs alleged that the standard of care required either hospitalization or quick referral to a stroke/TIA clinic to see a neurologist, the pamphlet on its face was directed to patients who’d been admitted to, and were being discharged from, a hospital. Thus, it was unlikely that consumers would believe that the pamphlet was recommending something less than the standard of care regarding hospitalization.

Even if a TIA patient treated in an ER got the pamphlet, that still wasn’t false advertising about the “the nature, characteristics, [or] qualities” of IHC’s services. It provided only very general information about stroke; IHC’s name only appeared twice: once as an author and once as a resource for stroke rehab and support groups on the last page.
Posted in http://schemas.google.com/blogger/2008/kind#post | Leave a comment

Statements to sellers of must-have component actionable under Lanham Act

TriStar Investors, Inc. v. American Tower Corp., No. 3:12–cv–0499, 2014 WL 1327663 (N.D. Tex. Apr. 3, 2014)

Cell towers are mostly owned and operated by tower companies, which rent wireless carriers the right to locate equipment on their towers.  Most towers are on property leased to tower companies.  TriStar is a tower company with about 650 tower locations (out of 135,000 in the US).  Defendant ATC operates about 22,800 tower sites. By mid-2013, TriStar had rights in land on which 594 cell towers currently or formerly operated by ATC, for about $50 million, or $85,000 per site. Its rights allow TriStar to operate cell towers on these sites when ATC’s current leases expire, in return for giving landowners a share of operating revenue; it’s already operating some of the towers.  ATC reported an 82% gross profit margin in 2012, while TriStar reported a gross profit margin of 55%. ATC alleged that TriStar’s agreements with two tower companies (SBA and Crown), in which TriStar agreed not to seek property rights in the land under towers owned or controlled by them, constituted an anticompetitive scheme to pay “supra-competitive” prices for property rights at ATC tower sites, “thus raising ATC’s costs to acquire future property rights, in the hopes that ATC would ultimately pay TriStar for a similar standstill agreement.” 

In response, ATC “began to be more proactive in seeking to acquire property interests for itself at its tower sites in order to control the use of the site after its current leases expired, and explored opportunities to move its towers or relocate its tower tenants to neighboring ATC towers.”  TriStar alleged that the results were false and misleading statements to landowners and sham litigation, allegedly securing future control at 2,944 sites where TriStar had made offers to landowners to acquire land rights under towers operated or formerly operated by ATC.

Nobody’s antitrust claims succeeded, because nobody’s antitrust claims do; the court found that ATC lacked standing to pursue a Sherman Act Section 1 counterclaim against TriStar, and that there was no dangerous probability of ATC successfully monopolizing the national market, given the competition from TriStar, Crown, and SBA (now allies of a sort—yay duopoly!).  ATC’s trade secret counterclaim based on its price terms survived, though barely; the court was dubious that price terms were actually trade secrets, but the parties didn’t submit enough evidence either way.  ATC’s tortious interference counterclaims also survived.  RICO claims against TriStar-related individuals were dismissed.

The Lanham Act piece: ATC argued that any allegedly false statements it made were in connection with efforts to get real property rights (easements/leases/etc.) rather than goods or services.  But ATC concededly provides services to landowners and wireless carriers; the statements to landowners were sufficiently connected to these services to support a Lanham Act claim. 

Still, ATC argued that its statements were made to suppliers—landowners supplying property—not purchasers, and thus couldn’t prompt a change in purchasing behavior.  Here, however, landowners could properly be characterized as consumers for these purposes.  TriStar’s evidence showed that ATC characterized landowners as its customers, for example in a mailing to a landowner, describing a commitment to being a “quality service provider for our customers and those companies and partners like you.”  The court found Health Care Compare Corp. v. United Payor & United Providers, Inc., No. 96–C–2518, 1998 WL 122900 (N.D.Ill. Mar. 13, 1998) persuasive. That case involved a middleman; the court found that statements to healthcare providers were actionable even though they were paid for services provided through the middleman’s network; the defendant’s business couldn’t succeed unless both payors and providers were convinced to use defendant’s services “with [defendant] providing each with access to the other.”

“Accordingly, where an entity is not a traditional ‘purchaser,’ statements to that entity may still be actionable under the Lanham Act if that entity is essential to the defendant’s ability to meet the needs of the entities that purchase its goods or services.”  Thus, the Lanham Act applied to ATC’s statements to landowners because ATC required property rights from them to do business with wireless carriers.  “[T]he importance of these property rights to ATC’s business relationship with wireless carriers places ATC’s statements to landowners properly within the bounds of a claim under the Lanham Act.”  Hmm.  Not sure this is consistent with Lexmark, but perhaps you can think of the “service” of managing the property and passing on revenues to the property owners as something that’s being advertised, and purchased with property rights instead of dollars?  Also, there is arguably an even stronger 1-to-1 correspondence between sales made to one and sales lost to another than in LexmarkGiven the need/desire of competitors to use the same land, there does seem to be a strong competitive interest at stake.

TriStar’s tortious interference claim likewise survived.

ATC argued that TriStar hadn’t submitted sufficient evidence of damages. TriStar alleged that ATC made false statements about TriStar to landowners to discourage them from conveying to TriStar.  (E.g., an ATC representative described TriStar’s method of operation as “highway robbery” and that the company was a “dirty, rotten, stinking outfit,” and a landowner testified that ATC’s statements left him “no options” but to stop “entertaining the thought of anything else other than [ATC].”) TriStar claimed injury as to 278 of the 2944 sites where they competed; ATC argued that at most TriStar showed that it lost property to ATC or paid more to secure a property interest because of ATC’s actions at 28 sites.  TriStar’s expert claimed to extrapolate from those sites to the remaining 250; he observed that as the number of incidents of misconduct by ATC increased, TriStar’s close rate decreased, despite the fact that TriStar increased its marketing expenditures and made allegedly superior offers.  His regression analysis was sufficient to survive summary judgment, allowing a jury to conclude that TriStar was injured at 278 sites.
Posted in http://schemas.google.com/blogger/2008/kind#post, standing | Leave a comment

Is flexibility the same as unpredictability?

Thought on the anti-fair use meme being used, mostly, to oppose the introduction of fair use in other countries: the criticism is that fair use’s flexibility means that it’s inherently and undesirably unpredictable. (See, e.g., the Kernochan Center’s submission to the Australian copyright inquiry.) But those aren’t synonyms. My elbow is flexible, not unpredictable. Only if the overall system is in trouble is flexibility also unpredictability. As numerous scholars such as Pam Samuelson, Mike Madison, and Matt Sag have shown, there are strong patterns in fair use cases on which reasonable people can rely.

Posted in http://schemas.google.com/blogger/2008/kind#post | Leave a comment

dispute over reliability of state of the art goes to trial

Nellcor Puritan Bennett LLC v. CAS Medical Systems, Inc., No. 2:11–cv–15697, 2014 WL 1304428 (E.D. Mich. Mar. 28, 2014)

The parties compete to sell cerebral oximeters, used by surgeons and anesthesiologists to monitor the oxygen saturation level of blood in a region of the brain.  Nellcor alleged that CAS falsely advertised that its oximeter was more accurate than Nellcor’s, in violation of the Lanham Act and state law.  CAS’s claim was based on studies that compared readings from competing cerebral oximeters to an estimate of the average oxygen saturation level of blood in the entire brain called “field saturation.” Nellcor’s main argument was that this was deceptive because field saturation is only a rough estimate about the entire brain, not a measurement of the saturation level of the relevant brain region.  Nellcor submitted “strong evidence” that field saturation differed from regional saturation, while CAS submitted evidence that field saturation was sufficiently accurate; though Nellcor’s evidence was stronger, the court found that there was still an issue of fact for trial.  The court did grant summary judgment (1) against CAS for its res judicata defense and (2) for CAS as to various smaller claims about the study’s unreliability, as well as claims about a page on CAS’s website that said it linked to summaries of recent studies involving CAS’s product when three of the ten studies were of Nellcor’s product.  (This last misdescription was changed soon after the lawsuit was filed.)

CAS’s claim was a “tests prove” or establishment claim. It can be falsified by showing (1) that the defendant’s test or study was not sufficiently reliable to permit one to conclude with reasonable certainty that it establishes the proposition for which it was cited, or (2) that the test, while sufficiently reliable, does not establish the proposition claimed in defendant’s advertising.  As noted above, Nellcor’s core argument was that field saturation wasn’t accurate or valid enough to compare the accuracy of cerebral oximeters; without a correct reference value, it’s impossible to do accurate comparative accuracy testing.  CAS argued that field saturation was the best available reference value, and that the FDA used it too.  Nellcor responded that the FDA accepted calculations using field saturation, but didn’t require or condone field saturation’s use as a reference.

The court found that a factfinder could find that field saturation is not an accepted or accurate reference value to compare the accuracy of cerebral oximeters; current measurements are just estimates, and in any event field saturation is different from regional saturation and oxygen levels may differ in different regions.  But a factfinder could also accept CAS’s evidence that, in healthy people, field saturation would be the same as regional saturation, and that the measurement was accurate enough to rely on.  CAS’s primary witness had a Ph.D. in electrical engineering, not medicine or physiology.  Another CAS witness published an article in 2012 that appeared to support Nellcor’s position; the court “look[ed] forward” to hearing him explain himself at trial and undergo cross-examination. Credibility determinations were for trial, though. (Or, hint hint, settlement.)

The court did reject several of Nellcorp’s criticisms of CAS-commissioned studies.  None of the alleged flaws made the studies unreliable.  It was not enough that the doctor running the study dropped some participants for unknown reasons, or that CAS provided draft abstracts and reviewed data calculations, when the doctor decided the final content.  Some issues of reliability could be explored at trial, such as whether studies on healthy patients could be extrapolated to the patients actually in need of oximeters.

As for the incorrect reference to studies on CAS’s webpage, the articles and their summaries all concluded that use of cerebral oximeters could improve patient outcomes; they weren’t comparative.  Nellcor didn’t show that the false attribution was material to a consumer’s purchasing decisions, “given the short amount of time the material was on the web site and the fact that articles only generally relate to cerebral oximetry.”

As for res judicata, CAS argued that the claims were barred because Nellcor filed and dismissed with prejudice an earlier false advertising case. The court disagreed: the claims were based on advertising after the case was dismissed, and thus could not have been brought earlier. Though one of the studies at issue was around earlier, it didn’t make the disputed “accuracy” statements (though CAS subsequently relied on it to do so). 

CAS also sought summary judgment on damages for lost profits.  CAS argued that its purchasers were sophisticated buyers who didn’t rely on marketing or advertising, but rather on their own evaluations in the field.  (Then why advertise?)  Taking the evidence in the light most favorable to Nellcor, Nellcor submitted sufficient circumstantial evidence of lost sales: it went from 100% of the market down to 80-85%, with 10-15% now CAS’s (and another company at 2-5%). Nellcor’s evidence was that CAS’s marketing strategy was to gain market share and get doctors’ and hospitals’ attention by making comparative accuracy claims as the key selling point.

Nellcor also sought corrective advertising damages. CAS argued that Nellcor should already have engaged in corrective advertising, because a plaintiff seeking such damages must timely counteradvertise unless financially incapable of doing so.  The Sixth Circuit hasn’t addressed the issue, but the Ninth Circuit hasn’t required counteradvertising around the time of the false advertising.  The Sixth Circuit has allowed separate recovery of counteradvertising expenses as reasonable business responses to false advertising.  Here, the court denied summary judgment.  If successful, “Nellcor is entitled to recover the amount of money necessary to engage in a corrective advertising campaign to correct for any damage to Nellcor’s goodwill proved to be caused by CAS’s false advertising.”
Posted in damages, http://schemas.google.com/blogger/2008/kind#post | Leave a comment

Juxtaposed claims can produce literal falsity

Groupe SEB USA, Inc. v. Euro–Pro Operating LLC, No. 14–137, 2014 WL 1316039 (W.D. Pa. Apr. 1, 2014) (magistrate judge)

The parties compete to sell household steam irons.  Plaintiff’s are sold under the name Rowenta, allegedly the top sellers by dollar value.  Defendant’s are sold under the name Shark.  Plaintiff alleged that the Shark 405 and 505’s packaging made literally false claims about Rowenta models. Both packages said: (1) “# 1 Most Powerful Steam* ” in the upper-right corner and (2) “More Powerful Steam v. Rowena®† at half the price” in the lower-right corner. (2) also appears on hang tags.  The first one was clarified on the bottom of the package with “offers more grams per minute (extended steam burst mode before water spots appear) when compared to leading competition in the same price range, at time of printing.” The second was likewise clarified with “††based on independent comparative steam burst testing to Rowenta [model number] (grams/shot).”

Plaintiff retained an outside lab to test using protocols from the International Electrotechnical Commission (“IEC”) and Euro–Pro’s own instructions for use.”  For each test, the Rowenta allegedly outperformed the Shark.

Euro-Pro argued that there should be an “intermediate” pleading standard for Lanham Act false advertising and that this complaint failed.  Without deciding the issue, even though there is no such thing as an intermediate pleading standard under the federal rules, the court held that the complaint would pass anyway.  It quoted the allegedly literally false statements and the disclaimers, and included photos of the packaging.  It identified industry standards for testing, and described the tests on which the falsity claim is founded. This was enough to allow Euro-Pro to defend itself.

Euro-Pro also argued that the complaint didn’t sufficiently allege literal falsity.  First, Euro-Pro argued that it had defined “steam power” on the packaging itself, so other measurements were irrelevant. But plaintiff’s tests also allegedly measured grams/minute and grams/shot, the same way the labeling did.  Of more general relevance, Euro-Pro argued that its “# 1 Most Powerful Steam” claim was made in comparison to the “leading competition in the price range,” not in comparison to Rowenta, but the complaint sufficiently alleged that the “# 1 Most Powerful Steam” statement is false because it appears “in juxtaposition” to the other statement comparing Shark to Rowenta.

This is another illustration of the rule that falsity, including literal falsity, can come from statements that are placed so close together that reasonable consumers would understand them together.  The disclaimers elsewhere on the packaging disclose that there are two different comparators, but small print disclaimers can’t fix a literally false message.

Finally, Euro-Pro argued that the complaint targeted statements it didn’t make: the complaint  “alleges that Euro–Pro ‘represents’ other claims to consumers, namely that the Euro–Pro products are ‘superior’ and ‘offer the same high-quality performance’ as SEB’s products,” but “does not identify advertising that contains these statements and therefore these allegations do not support SEB’s purported literal falsehood claim.”  However, plaintiff responded that the “more powerful steam/half the price” claim was “obviously a claim of superiority that deceives consumers into the false belief that the much lower-priced Shark steam irons offer the same high-quality performance of the Rowenta irons.” The court agreed.
Posted in http://schemas.google.com/blogger/2008/kind#post | Leave a comment

failure to conform to dog breed standard isn’t literally false

It’s really more of a guideline.

Wagner v. Circle W Mastiffs, No. 2:08–CV–00431, 2014 WL 1308713 (S.D. Ohio Mar. 31, 2014)

I’m skipping the many and complex defamation claims.  The Lanham Act bit: the Lanham Act plaintiffs alleged that the defendant Williamsons “falsely advertised that their maskless dogs are American Mastiffs, in derogation of the breed standard.”  In the absence of evidence of consumer deception, the question was literal falsity, and plaintiffs argued that dark masks are required according to the breed standard.  The court found no literal falsity.

A breed standard, the court found, “defines the aspirational characteristics of a particular breed of dog.”  A maskless dog might not be registrable as an American Mastiff because the absence of a mask is “relatively significant,” but an owner of that dog can still (truthfully) represent that dog as being the offspring of purebred American Mastiff dogs.  “Whether a dog may be considered an American Mastiff if it sufficiently aligns with the breeding standard, or whether it may be considered an American Mastiff simply because it is the offspring of two registered American Mastiffs, seems to the Court to be a matter of semantics and philosophy.”  Thus, advertising the offspring as an American Mastiff was not literally false, especially since it was undisputed that the Williamsons didn’t hide the masklessness of some of their dogs.
Posted in http://schemas.google.com/blogger/2008/kind#post | Leave a comment

What does Lexmark mean for the "commercial advertising or promotion" test?

Goodman v. Does 1–10, No. 4:13–CV–139, 2014 WL 1310310 (E.D.N.C. Mar. 28, 2014)

The first post-Lexmarkopinion I’ve seen, and a thoughtful one at that. The complaint alleged various defamation and unfair competition claims based on postings on a website, localdirtbags.com, run by defendant Lagoy.  Goodman, a licensed auto mechanic who owns a number of auto repair businesses in North Carolina, “has been the target of an extraordinarily aggressive smear campaign on the localdirtbags website,” which is “apparently devoted to ruining Goodman’s personal and business reputation.”  Accusations include overcharging customers and criminality. Many of the statements about Goodman are made in the site’s blog posts, though users can also post comments. Lagoy admitted that she created the site and authored many of the blog posts; Goodman alleged that Lagoy posted most of the comments under various pseudonyms and that any positive comments are immediately deleted.

Was this “commercial advertising or promotion”? The Fourth Circuit hasn’t explicitly ruled, but several cases within the circuit have used the Gordon & Breach four-part test: (1) commercial speech; (2) by a defendant who is in commercial competition with plaintiff; (3) for the purpose of influencing consumers to buy defendant’s goods or services (4) disseminated sufficiently to the relevant purchasing public.  “[C]onsumer or editorial comment” that might be disparaging isn’t covered, according to the legislative history.

The court suggested that concerns for protecting free speech drove the “intricate body” of prudential standing law, now eliminated “[i]n one fell swoop” by Lexmark. Because the Supreme Court expressed no opinion on “commercial advertising or promotion,” the court here stuck with the standard test, though it noted below that part (2) probably has to be modified to comport with Lexmark.

Here, Goodman failed sufficiently to allege that the posts constituted commercial speech or that they were made by a defendant in competition with Goodman. The only factual allegation relevant to commerciality was that the website operator put the defamatory content up “in order to drive traffic to the blog, and increase the monetary value of the blog, in a collective effort to promote and sell the blog to a third party.” That’s plainly insufficient to make it commercial speech.  “As can be seen from even a cursory review of the comments and articles discussed above, the statements do not propose a commercial transaction in any traditional sense of that phrase and the court cannot reasonably infer that the statements relate solely to the speaker and his audience’s economic interests.”  While the content might be defamatory, it’s not plausibly commercial speech.

The complaint also failed to allege that any defamatory statements came from Goodman’s competitors, who would have an economic interest in disparaging Goodman’s businesses.  A pure competition requirement was “somewhat in question” after the Lexmark, which held that direct competition isn’t required for standing; “unfair competition” isn’t limited to actions between competitors.  But that doesn’t mean that a lawsuit like this one is ok under the Lanham Act, since the complaint failed to allege “any reasonable commercial interest in the content of the postings.”  Lexmark doesn’t eliminate the commerciality requirement.  The court couldn’t reasonably infer that the posts reflected commercial competitors’ statements; on their face, they purported to be consumer reviews by parties with no commercial interest in the postings themselves.  “Goodman essentially concedes as much by alleging that the Defendants’ commercial interest in this case is in driving traffic to the website, not diverting business from Goodman to his competitors.”

The issue was complicated because Goodman didn’t know the identities of the defendants.  It was possible—though not plausible—that some of the postings were from commercial competitors. None of the statements alleged outright encouraged readers to take business to a specific competitor.  “Although in general a commercial advertisement under the Lanham Act does not need to contain a business solicitation, the fact that no competitor solicitations occur in any of the numerous postings on the website cuts against any potential inference that these postings come from competitors.”

The court dismissed the Lanham Act claim with prejudice:

Allowing leave to amend on the remote possibility that discovery will reveal that Goodman’s competitors are responsible for the postings would allow a plaintiff to maintain a false advertising claim against virtually any website that allows users to post negative online reviews. Mindful of the limited jurisdiction of the federal courts, the court is concerned about setting a precedent where a plaintiff can manufacture federal jurisdiction on the questionable allegations presented by these particular facts.

The court specified, however, that if it were presented with a case in which a plaintiff had a good faith belief that anonymous posters were competitors (citing NTP Marble as an example), it would be open to allowing that claim to proceed. Also, “nothing in this ruling precludes Goodman from later asserting a Lanham Act claim, should he become aware of facts which cause him to have a good faith belief that the anonymous posters were competitors.” But under the circumstances, the court declined to exercise supplemental jurisdiction over the state law claims.
Posted in commercial speech, defamation, http://schemas.google.com/blogger/2008/kind#post, standing | Leave a comment